Study of the Reishi mushrooms dry extract hepatoprotective properties

Authors

DOI:

https://doi.org/10.24959/ubphj.19.232

Keywords:

Reishi mushrooms, paracetamol, hepatitis, dry extract, hepatoprotective properties

Abstract

Topicality. It is promising to search for new effective hepatoprotectors of natural origin, which are aimed at normalizing homeostasis in liver, increasing resistance to pathogenic influences, normalizing functional activity of liver, stimulating regenerative processes. Therefore, the issues of providing these drugs with a therapeutic process are relevant.
Aim. To investigate the hepatoprotective properties of the Reishi mushrooms dry extract in an experiment on rats with simulated paracetamol hepatitis.
Materials and methods. Studies were conducted on 60 white male rats, weighing 180-210 g at the age of 5-5.5 months. The rats were divided into 10 groups, each of which included 6 animals. Acute hepatitis was modeled by intragastric paracetamol administering at a dose of 1250 mg/kg 1 time per day as a suspension in a 2 % starch gel solution for 2 days. Correction of toxic damage was performed with dry extract of Reishi mushrooms, which was administered intragastric 2 hours before the administration of paracetamol and daily after the lesion at a dose of 100 mg/kg of body weight. “Silibor” was selected as a comparison drug, which was administered according to the same scheme as Reishi extract at a dose of 20 mg/kg of animal body weight. Euthanasia of rats was performed using barbamyl sodium on the 3rd, 7th and 10th day from the onset of the lesion.
Results and discussion. The study subjected the homogenate of liver and serum. Blood was taken from the heart of animals. Endogenous intoxication of animals was assessed by the AlAT, AsAT, GGTP, ALP activity and the value of thymol sample after the corrective factors introduction.
Conclusions. Studies have found a positive effect of Reishi mushrooms dry extract on the permeability of plasma membranes of hepatocytes in animals with paracetamol hepatitis, which is confirmed by the normalization of the activity of membrane-dependent enzymes – AlAT, AsAT, GGTP, ALP and a decreasing of thymol sample. This indicates the hepatoand membrane-protective properties of the investigated phytopreparation and will allow its further successful use in liver diseases.

Author Biographies

I. Herasymets, SHEI "I.Ya. Horbachevsky Ternopil National Medical University"

PhD in Pharmacy, associate professor of the department of pharmacology with clinical pharmacology

L. Fira, SHEI "I.Ya. Horbachevsky Ternopil National Medical University"

doctor of biological sciences, professor, head of the department of pharmacy NNI PO

I. Medvid, SHEI "I.Ya. Horbachevsky Ternopil National Medical University"

PhD in Medicine, assistant of the department of microbiology, virology and immunology

References

Zahaiko, A. L., Krasilnikova, O. A., Zaika, S. V., Seniuk, I. V. (2013). Ukrayinskyi biofarmatsevtychnyi zhurnal, 1 (24), 4–8.

Jang, S.–H., Cho, S., Yoon, H.–M., Jang, K.–J., Song, C.–H., & Kim, C.–H. (2014). Hepatoprotective Evaluation of Ganoderma lucidum Pharmacopuncture : In vivo Studies of Ethanol-induced Acute Liver Injury. Journal of Pharmacopuncture, 17 (3), 16–24. https://doi.org/10.3831/kpi.2014.17.022

Wang, J., Cao, B., Zhao, H., & Feng, J. (2017). Emerging Roles of Ganoderma Lucidum in Anti–Aging. Aging and Disease, 8 (6), 691. https://doi.org/10.14336/ad.2017.0410

Zeng, P., Guo, Z., Zeng, X., Hao, C., Zhang, Y., Zhang, M., … Zhang, L. (2018). Chemical, biochemical, preclinical and clinical studies of Ganoderma lucidum polysaccharide as an approved drug for treating myopathy and other diseases in China. Journal of Cellular and Molecular Medicine, 22 (7), 3278–3297. https://doi.org/10.1111/jcmm.13613

Dovhyi, R. S., Makarenko, O. M., Rudyk, M. P. (2011). Visnyk ukrainskoi medychnoi stomatolohichnoi akademii, 4–1 (36), 128–134.

Gross, D., Tolba, R. (2015). Ethics in Animal-Based Research. Eur. Surg. Res, 55 (1–2), 43–57. https://doi.org/10.1159/000377721

Vashkeba-Bitler, E. M. (2014). Visnyk problem biolohii i medytsyny, 4 (4), 58–62.

Tarrant, J., Meyer, D., & Katavolos, P. (2013). Use of optimized aminotransferase methods in regulated preclinical studies. Veterinary Clinical Pathology, 42 (4), 535–538. https://doi.org/10.1111/vcp.12082

Kamyshnikov, V. S. (2009). Spravochnik po kliniko-biohimicheskim issledovanijam i laboratornoj diagnostike. Moskva : MEDpress-inform, 43.

Hzhehotskyi, M. R., Zaiachkivska, O. C. (2001). Systema krovi. Fiziolohichni ta klinichni osnovy. Lviv : Svit, 173.

Shelamova, M. A., Insarova, N. I., Lieshchienko, V. H. (2010). Statisticheskii analiz miediko-biologichieskikh dannykh s ispolzovaniiem programmy EXCEL. Minsk : BGMU, 96.

Jannot, A.–S., Agoritsas, T., Gayet–Ageron, A., & Perneger, T. V. (2013). Citation bias favoring statistically significant studies was present in medical research. Journal of Clinical Epidemiology, 66 (3), 296–301. https://doi.org/10.1016/j.jclinepi.2012.09.015

Shabat, Y., Ya’acov, A. B., & Ilan, Y. (2018). Alpha–1 Anti–trypsin Exerts a Hepatoprotective Effect on Immune-mediated Hepatitis and Acetaminophen-induced Liver Injury. Journal of Clinical and Translational Hepatology, 6 (4), 345–349. https://doi.org/10.14218/jcth.2018.00030

Published

2019-11-19

Issue

Section

Pharmacology and biochemistry